FDA To Weigh Public Input On Biosimilars Program

Law360, New York (December 6, 2011, 7:29 PM EST) -- The U.S. Food and Drug Administration said Monday it would hold a public hearing to seek stakeholder input on the agency’s proposed user fee program for biosimilar biological products, a move that won praise from the pharmaceutical industry.

The FDA said that on Dec. 16 and 17 it would hear public comments on the potential user fee program, which would collect money from applicants to help fund reviews of biosimilars, biological products that are similar to other biological medicines the agency has already licensed.

The health...
To view the full article, register now.